Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 5,722

Document Document Title
WO/2024/025151A1
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...  
WO/2024/025353A1
The present invention relates to: an organic compound employed as an organic layer material, such as an electron-blocking layer in an organic light-emitting device; and an organic light-emitting device comprising same. When the compound ...  
WO/2024/019661A1
The present disclosure concerns a method of promoting the ubiquitination of MK2 protein, comprising contacting the MK2 protein with a compound of Formula (I) or a salt, solvate, stereoisomer or prodrug thereof. The present disclosure als...  
WO/2024/014716A1
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic layer.  
WO/2024/009283A1
Angiotensin AT2 receptor antagonists have been clinically validated for the treatment of chronic neuropathic pain. We discovered a series of lead compounds comprising a trisubstituted heterocyclic core that show high in vitro (sub-nanomo...  
WO/2024/009308A1
The present invention involves novel TRPV2 blockers, pharmaceutical compositions comprising the same and uses thereof for the treatment of inflammatory response in inflammation mediated disease processes.  
WO/2024/005431A1
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.  
WO/2024/005428A1
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.  
WO/2023/237732A1
The invention concerns compounds having antiviral activity, in particular having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising th...  
WO/2023/235929A1
The present disclosure relates generally to compounds with anti-cancer and/or anti-fibrotic properties. In particularn the disclosure relates to functionalised benzopyran compounds, the preparation thereof, and their use.  
WO/2023/239193A1
The present invention provides a novel compound and an organic light-emitting device using same.  
WO/2023/234603A1
The present invention relates to an organic compound employed in an organic layer, such as a hole transport layer or an electron blocking layer, in an organic light-emitting device. The organic compound according to the present invention...  
WO/2023/225916A1
Disclosed is a method for preparing 4-thioflavone compound from a hydroxychalcone compound and xanthate, wherein the hydroxychalcone compound and the xanthate react in a solvent to prepare a thioflavone compound. In view of the huge appl...  
WO/2023/227695A1
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...  
WO/2023/227117A1
Provided in the present invention is a 3C-like protease inhibitor as shown in formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof. Also provided in ...  
WO/2023/228790A1
The present invention provides a fluorescent-probe solution in which the fluorescent probe is inhibited from decreasing in purity. This fluorescent-probe solution comprises a compound represented by formula (I) or a salt thereof, at leas...  
WO/2023/229228A1
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device including same.  
WO/2023/224020A1
Provided is a compound represented by formula (1). (The symbols in formula (1) are as defined in the specification.) Also provided are an organic electroluminescent element that contains the compound and an electronic device that include...  
WO/2023/223855A1
The present invention provides: a compound which is represented by formula (1) (each of the symbols in formula (1) is as defined in the description); an organic electroluminescent element which contains this compound; and an electronic d...  
WO/2023/222103A1
The present disclosure relates to crystal forms of a triazine dione derivative and a preparation method therefor. Specifically, the present disclosure relates to different crystal forms of (S)-6-((1-(2-fluoro-5-methylphenyl)ethyl)amino)-...  
WO/2023/217058A1
The present invention relates to a method for preparing a compound as shown in a formula II, comprising: in an organic solvent, reacting a compound shown in formula III with a compound shown in formula IV under the action of organic meta...  
WO/2023/217018A1
Provided is a compound having a structure of formula (I), which has cancer treatment activity. Further provided are a preparation method for the compound of formula (I), and a pharmaceutical composition comprising the compound.  
WO/2023/219399A1
The present specification relates to a compound represented by Chemical Formula 1, a coating composition comprising the compound represented by Chemical Formula 1, an organic light-emitting device using same, and a manufacturing method t...  
WO/2023/215367A1
Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...  
WO/2023/202583A1
Disclosed are an FXR regulator and use thereof, and specifically disclosed are a compound represented by formula I, or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, ...  
WO/2023/205226A1
One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) are useful for inhibiting mutant KIT prote...  
WO/2023/202664A1
Disclosed herein are fused bi-cyclic compounds used as Small Molecule IL-17A Modulators. Disclosed herein is the use of these Small Molecule IL-17A Modulators for the use of decreasing IL-17 activity by inhibition, and the use of such co...  
WO/2023/197987A1
Disclosed are a novel compound as represented by formula (I-b) having an ENPP1 inhibitory activity, a pharmaceutical composition comprising the compound, an intermediate useful for preparing the compound, and a method for treating cell p...  
WO/2023/200196A1
The present invention relates to an organic compound employed in an organic layer in an organic light-emitting device, such as a hole transport layer and an electron blocking layer. The organic compound according to the present invention...  
WO/2023/200195A1
The present invention relates to an organic compound, which is employed for an organic layer, such as a hole transport layer or an electron block layer, of an organic light emitting diode. The organic compound according to the present in...  
WO/2023/196512A1
Disclosed are compounds of formula I, formula I-1, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof that are useful for modulating or degrading bromodomain (e.g., BRD4).  
WO/2023/195787A1
An organic compound represented by chemical formula 1 of the present invention can implement excellent hole transfer characteristics. In addition, at least one of a hole transport layer and a hole transport aid layer of an organic light ...  
WO/2023/194458A1
The present invention relates to a compound of formula (I) or an enantiomer, diastereomer, N-oxide, solvate or pharmaceutically acceptable salt thereof. The present invention further relates to a compound of formula (I) for use in a meth...  
WO/2023/195791A1
The present invention relates to a phenylpropenone backbone compound, which is a novel chromanone or a ring-opened form thereof, and a composition for preventing or treating multiple myeloma comprising same as an active ingredient. The c...  
WO/2023/191353A1
The present specification relates to a heterocyclic compound of chemical formula 1, an organic light-emitting device comprising same, and a composition comprising same for forming an organic layer.  
WO/2023/180964A1
The present invention relates to pyrazine amide derivative compounds, such as those according to formula (I) and compositions including said compounds, The invention also provides such pyrazine amide derivative compounds for use in the t...  
WO/2023/180189A1
Disclosed are novel viral Mpro inhibitors according to Formula (I), their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also disclosed are methods of using such compounds and compositions to inhibit Mpro and...  
WO/2023/182519A1
An ascorbic acid derivative or a salt thereof that contains a structure in which at least one of hydroxyl groups contained in ascorbic acid has been substituted with an ether bond attached to a carbon atom.  
WO/2023/178302A1
Natural product-like compounds are derived from the sesquiterpene lactone parthenolide. Methods are provided for the generation of novel natural product-like molecules obtained through the chemoenzymatic reelaboration and modification of...  
WO/2023/171920A1
Provided is a high-refractive-index carbazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...  
WO/2023/171781A1
To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. The present inventors have examined compounds useful as an active ingredient of a pharmaceutical composition for treat...  
WO/2023/169436A1
Disclosed in the present invention are a benzo bicyclic compound, and a preparation method and application thereof. Specifically disclosed is a compound, which is a compound as shown in formula (X), or a stereoisomer, geometric isomer, t...  
WO/2023/166303A1
The invention relates to compounds of formula (I): (I) and related aspects.  
WO/2023/160672A1
The present disclosure provides LPA antagonists of formula I, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.  
WO/2023/160614A1
Disclosed in the present invention are a compound as an FAK inhibitor and a use thereof. Specifically, involved are a compound represented by general formula (1) and a preparation method therefor, and a use of the compound represented by...  
WO/2023/155710A1
The present invention belongs to the field of medicinal chemistry, and relates to an IKZF2 degradation agent, a pharmaceutical composition comprising same and use thereof. Specifically, the IKZF2 degradation agent has a structure represe...  
WO/2023/155927A1
The present disclosure provides an inhibitor, represented by formula I, of interaction between YAP/TAZ and TEAD, preparation thereof, a pharmaceutical composition thereof and use thereof. The compound provided in the present disclosure c...  
WO/2023/153169A1
The present disclosure provides an organic compound represented by general formula (1). (In general formula (1), R1 to R20 are each independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, an...  
WO/2023/150776A1
The present disclosure provides water-soluble and low-aggregation NIR- and SWIR- active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.  
WO/2023/146244A1
The present disclosure provides a benzodioxane scaffold compound having AIMP2-DX2 inhibitory activity or a pharmaceutically acceptable salt thereof. The present disclosure also provides a composition comprising such a compound or a pharm...  

Matches 51 - 100 out of 5,722